Continuity Biosciences Welcomes Vicky Papoutsis to Its Board of Directors
Continuity Biosciences Welcomes Vicky Papoutsis to Its Board of Directors
Continuity Biosciences, a clinical-stage biotech company specializing in precision drug delivery, has announced the appointment of Vicky Papoutsis to its Board of Directors. With over 25 years in the biopharmaceutical industry focusing on business development and corporate strategy, Papoutsis is set to play a crucial role in advancing the company’s clinical and partnership initiatives.
As Continuity progresses past the developmental stages of its platform technologies into active clinical trials, the timing of Papoutsis' appointment is pivotal. The company has made significant strides, including its lead pancreatic cancer drug now under examination in clinical settings, necessitating enhanced strategic partnerships and execution. Papoutsis' previous experience, having successfully structured numerous licensing deals and corporate transactions, aligns perfectly with Continuity’s needs as it seeks to expand its collaboration landscape.
Currently, Vicky Papoutsis is the Executive Vice President and Chief Strategy Officer at TerSera Therapeutics. Throughout her extensive career, she has been at the forefront of key industry trends, managing significant mergers and acquisitions, and steering corporate strategy initiatives across various organizations. Notably, she has overseen the negotiation of over 30 strategic transactions and has helped launch three successful bioscience startups supported by private equity funding.
Robert Whitehead, Co-Founder and Executive Chair of Continuity Biosciences, expressed his enthusiasm regarding Papoutsis' joining the team, stating: "I have had the privilege of collaborating with Vicky on numerous transactions throughout my career and hold her strategic judgment and professionalism in high regard. As we sharpen our focus on clinical executions and desired partnerships, Vicky’s extensive experience will be of immense value to us. We are thrilled to welcome her to the Board."
Upon her appointment, Papoutsis remarked, "Joining Continuity Biosciences at this crucial juncture of development is an honor for me. The company has built an exceptional team composed of management, scientific advisors, and board members, all of whom are dedicated to innovating precision drug delivery across myriad therapeutic areas. I am eager to contribute to its strategic trajectory and help strengthen its partnerships to enhance patient outcomes."
Papoutsis adds a wealth of business development acumen and transaction expertise to a Board that has been curated to embody deep knowledge of biotechnology innovations, pharmaceutical developments, healthcare delivery, corporate governance, finance, operations, regulatory matters, and strategic business progression. Whitehead shed light on the unique blend of experiences within the Board, emphasizing their collective expertise in founding biotechnology firms, overseeing innovative medicines’ commercialization, and advising top-tier life sciences corporations while managing substantial investments and executing major deals.
Continuity Biosciences is advancing its portfolio through various precision drug delivery platforms aimed at providing localized, sustained, and controlled therapeutic administration. The company is currently working on programs not only within oncology but also Type 1 diabetes, endocrinology, HIV prevention, and medical aesthetics. Collaborations with esteemed academic institutions, scientific advisors, and strategic partners support its robust pipeline development.
For additional details about Continuity Biosciences and its innovative approaches to drug delivery, interested parties can visit their official website at continuitybiosciences.com.
About Continuity Biosciences
Continuity Biosciences is dedicated to developing advanced drug delivery technologies that ensure localized, sustained, and precisely controlled therapy administration. The breadth of its initiatives spans diverse medical domains such as oncology, endocrinology, and HIV prevention among others. The company is actively pursuing innovative methodologies to improve the therapeutic landscape while addressing significant patient needs globally.
Other Board Members
Continuing with the strategic goals set within its Board of Directors, Continuity includes prominent figures such as:
- - Michael Fowler: An expert in investment operations, currently overseeing Affordable Housing Partners, Inc.
- - Monica Reed, M.D.: A seasoned leader in integrated healthcare systems.
- - Josephine M. Torrente: Formerly a partner in a leading healthcare law firm, specializing in regulatory matters.
- - Ramakrishna Venugopalan, Ph.D.: A prominent figure from AbbVie, known for leading successful pharmaceutical initiatives.
- - Allen Weiss: Recognized for his operational leadership at Walt Disney Parks and Resorts.
This diversity within the board promises a bright future for Continuity as it continues its mission of transforming how therapy is delivered, aiming for revolutionary advancements in patient care.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.